Abbott India Ltd. News and Updates

Name: Latest research reports of Abbott India Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news on Abbott India Ltd. from all sources in a single place.

Load latest

Abbott India Ltd.

08 Nov 2024

30225.00

0.10%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

we maintain a BUY rating on the stock. We have set a target price of Rs 31,420/share, which implies an upside potential of 12% from the CMP.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

07 Nov 2024

30225.00

0.10%

Abbott India Q2 Results: Profit Rises 15%, Beating Estimates

NDTV Profit

Abott India reported a net profit of Rs 359 crore, compared with the consensus estimate of Rs 237 crore.

Sharekhan increased Buy price target of Abbott India Ltd. to 34470.0 on 17 Sep, 2025.

Abbott India Ltd.

26 Oct 2024

30225.00

0.10%

Pick of the Week:28 October 2024

Buy: Abbott India Ltd.

Target

Axis Direct

We recommend a BUY with a target price of Rs 31,420/share (46.5x P/E for FY26E), implying an upside of 10% from the CMP.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

28 Aug 2024

30225.00

0.10%

Abbott India recalls Pentids antibiotic batches over packaging issues

Business Standard

Pentids are widely prescribed for treating bacterial infections of the respiratory tract, throat, lungs, nose, skin, and sexually transmitted diseases like syphilis

Sharekhan increased Buy price target of Abbott India Ltd. to 34470.0 on 17 Sep, 2025.

Abbott India Ltd.

08 Aug 2024

30225.00

0.10%

Here's why Abbott India stock price surged 5% on August 8; details here

Business Standard

The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).

Abbott India Ltd. has an average target of 35337.00 from 4 brokers.

Abbott India Q1 results: PAT rises 13% to Rs 328 cr, income at Rs 1,625 cr

Business Standard | 07 Aug 2024

Abbott India Ltd.

08 Aug 2024

30225.00

0.10%

Healthy earnings: growth momentum to continue

Buy: Abbott India Ltd.

Target

Sharekhan

Earnings were in line with our estimates, where sales grew by 5% y-o-y to Rs 1,557 crore (1.6% below our estimates), EBITDA grew by 10% y-o-y to Rs 3,910 crore.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

08 Aug 2024

30225.00

0.10%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We have BUY on the Stock

Abbott India Ltd. has an average target of 35337.00 from 4 brokers.

Abbott India Ltd.

19 May 2024

30225.00

0.10%

Abbott India eyes 45% female representation in management team, 1 lakh youths in STEM programmes by 2030

Business Today

Addressing the global STEM worker shortage, Abbott plans to create opportunities for over 1,00,000 youths, including 50% from underrepresented groups, to participate in STEM programmes and internships by 2030.

Abbott India Ltd. is trading below all available SMAs

Abbott India Ltd.

12 May 2024

30225.00

0.10%

Sailing through turbulence

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q4FY24 revenue growth of 7% was slightly below expectation of 9%; however, its 9.4% growth in FY24 was still ahead of industry growth of ~8%. Sequential drop of 197/407bps in gross/EBITDA margin was on account of higher third-party sourcing and higher overhead cost.